Andrew Solomon

2 months ago | jdsupra.com | Christopher A. Jones |James Kim |Andrew Solomon

On April 15, 2025, President Trump signed the Lowering Drug Prices by Once Again Putting Americans First Executive Order (Executive Order). The Executive Order revives and expands several pharmaceutical pricing and payment reforms from President Trump’s first term, with a goal of curbing drug costs to patients. This offers a highly anticipated glimpse into the Administration’s position on drug manufacturers, Pharmacy Benefit Managers (PBMs) and providers.

2 months ago | bizmag.co.za | Andrew Solomon |Heidi Kruger

The potential for personalisation in marketing for customer engagement is alluring, but effective personalisation is still rare in business. Getting there is more of a crawl than a sprint, and there are reasons for that. On a scale from creepy to cool, personalisation – and its newer offspring, hyper-personalisation – might just be heading in the right direction.

Mar 26, 2025 | bizcommunity.com | Karabo Ledwaba |Andrew Solomon

2 days7 days30 daysBy Industry Show moreAdvertise your job vacancies Meta has agreed to stop targeting adverts at an individual Facebook user after she filed a lawsuit against the tech giant. Tanya O’Carroll, a London-based tech policy and human rights advocate, challenged Facebook’s use of personal data for targeted advertising, arguing that users have the right to object under UK data protection laws.

Mar 21, 2025 | neurologylive.com | Andrew Solomon |Isabella Ciccone

WATCH TIME: 8 minutes“The diagnostic process [for multiple sclerosis] should be thinking about our diagnostic criteria and making sure that patients fulfill that criteria but also considering other diagnoses that can mimic [the disease] along the way.”The MS Differential Diagnosis Consortium (MSDDC), sponsored by the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), is led by Andrew Solomon, MD, as chair, with Jeffrey Cohen, MD, as co-chair.

Mar 10, 2025 | jdsupra.com | Chad Landmon |Andrew Solomon

March 10, 2025 To embed, copy and paste the code into your website or blog: Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not have been listed in the FDA’s Orange Book since the claims of the patents in question did not recite the active drug substance.